Shelf life (days): 1460.0
Formulation: A crystalline solid
Formal Name: N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, monohydrochloride
Purity: ≥98%
Formula Markup: C19H27N5O4 / HCl
Formula Weight: 425.9
CAS Number: 81403-68-1
Notes: Alfuzosin is a post-synaptic α1-adrenergic receptor antagonist commonly used to improve lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).{18261,18269} It displays high-affinity with non-selectivity for the three known human α1 adrenoceptors (pKi = 8.0, 8.0, and 8.5 for α1A, α1B, and α1D, respectively).{18268} Consistent with a role for α1 adrenoceptors in mediating contraction of smooth muscle, alfuzosin was first described as having anti-hypertensive effects with peripheral vasodilator properties.{18261} In patients with BPH, alfuzosin increases mean urinary flow rate and decreases residual volume.{18269} Alfuzosin produces minimal vasodilatory and sexual function side effects.{18262,18266,18267}
Deutsch
English
